Selected Publications

• Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity. Ioannis Evangelos Louloudis, Yi Bin Chen, Nikolaos Spyrou, Amin Alousi, Nikolaos Katsivelos, Francis Ayuk, Daniela Weber, William J. Hogan, Aaron M. Etra, Muna Qayed, Paibel Aguayo-Hiraldo, Yu Akahoshi, Monzr M.Al Malki, Javier Bolaños-Meade, Chantiya Chanswangphuwana, Marcio Diniz, Matthias Eder, Elizabeth Hexner, Carrie L. Kitko, Sabrina Kraus, Pietro Merli, Timothy Olson, Margaret L. MacMillan, Joseph Pidala, Ran Reshef, Tal Schechter, Matthias Wölfl, Janna Baez, Gilbert Eng, Sigrun Gleich, Rachel Young, Ryotaro Nakamura, James L.M. Ferrara, John E. Levine. Transplantation and Cellular Therapy
• The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD. Yu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, Ioannis E. Louloudis, Paibel Aguayo-Hiraldo, Francis Ayuk, Chantiya Chanswangphuwana, Hannah K. Choe, Matthias Eder, Aaron M. Etra, Elizabeth O. Hexner, Carrie L. Kitko, Sabrina Kraus, Pietro Merli, Timothy S. Olson, Ivan Pasic, Muna Qayed, Ran Reshef, Tal Schechter, Julia Marx, Evelyn Ullrich, Ingrid Vasova, Daniela Weber, Matthias Wölfl, Robert Zeiser, Janna Baez, Gilbert Eng, Sigrun Gleich, Steven Kowalyk, George Morales, Nikolaos Spyrou, Rachel Young, Zachariah DeFilipp, William J. Hogan, Ryotaro Nakamura, John E. Levine, James L.M. Ferrara. Blood advances
• Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD. Aaron Etra, James L.M. Ferrara, John E. Levine. Blood